Drug Trial Radar · NCT07264673
A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.
Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Apr 17, 2025
Primary completion
Oct 2027
Study completion Oct 2029
Sponsor
- Lead sponsor
- Fondazione Ricerca TraslazionaleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II randomized study investigating whether a combination maintenance with Cemiplimab and OSE2101 (TEDOPI®) could increase ctDNA clearance rate versus standard maintenance therapy in HLA-A2 positive NSCLC patients not progressing after 4 cycles of chemo-immunotherapy.
Conditions
- NSCLC
Interventions
TedopiDrug
Cemiplimab + OSE2101 (TEDOPI®) (ARM B: experimental arm)
CemiplimabDrug
Cemiplimab +/-Pemetrexed (ARM A: standard arm)
Primary outcomes
What the sponsor says the trial is designed to measure.
- ctDNA clearance rateTime frame: 48 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena
Roma, RM, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.